申请人:Yasuma Tsuneo
公开号:US20110301155A1
公开(公告)日:2011-12-08
The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like, and the like.
A compound represented by the formula (I):
wherein R
1
is an optionally substituted 4- to 7-membered nitrogen-containing heterocyclic group, optionally substituted carbamoyl, or optionally substituted sulfamoyl; R
2
is optionally substituted alkyl, optionally substituted alkoxy, an optionally substituted 3- to 7-membered cyclic group, —SR′, —SOR′, or —SO
2
R′ (R′ is a substituent); R
3
is hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, —O-Cy (Cy is an optionally substituted 3- to 7-membered cyclic group which may be condensed with benzene), —SR″, —SOR″, or —SO
2
R″ (R″ is a substituent), or an optionally substituted 3- to 7-membered cyclic group which may be condensed with benzene; R
4
is hydrogen, or optionally substituted alkyl; provided that when R
3
is hydrogen, halogen, or methoxy, then R
2
is not optionally substituted alkyl, or optionally substituted alkoxy; further provided that 5-[5-[(2S)-2-amino-3-phenylpropyl]oxy}-2-(3-furyl)pyridin-3-yl]-N-pyridin-4-yl-1H-indazol-3-amine and 5-[
5
-[(2S)-2-amino-3-phenylpropyl]oxy}-2-(3-furyl)pyridin-3-yl]-1-(4-methoxybenzyl)-N-pyridin-4-yl-1H-indazol-3-amine are excluded; or a salt thereof.
本发明旨在提供一种葡萄糖激酶激活剂,可用作药物剂,例如用于预防或治疗糖尿病、肥胖症等药物剂,并且类似。化合物的结构式如下(I):其中,R1是可选取的取代的4-至7-成员含氮杂环基团、可选取的取代的氨基甲酰基或可选取的取代的磺酰基;R2是可选取的取代的烷基、可选取的取代的烷氧基、可选取的取代的3-至7-成员环基团、-SR'、-SOR'或-SO2R'(R'是一个取代基);R3是氢、卤素、可选取的取代的烷基、可选取的取代的烯基、可选取的取代的烷氧基、-O-Cy(Cy是一个可选取的3-至7-成员环基团,可以与苯并环缩合)、-SR''、-SOR''或-SO2R''(R''是一个取代基),或可选取的取代的3-至7-成员环基团,可以与苯并环缩合;R4是氢或可选取的取代的烷基;但是,当R3为氢、卤素或甲氧基时,R2不是可选取的取代的烷基或可选取的取代的烷氧基;进一步提供,5-[5-[(2S)-2-氨基-3-苯基丙基]氧基}-2-(3-呋喃基)吡啶-3-基]N-吡啶-4-基-1H-吲唑-3-胺和5-[5-[(2S)-2-氨基-3-苯基丙基]氧基}-2-(3-呋喃基)吡啶-3-基]-1-(4-甲氧基苯基)-N-吡啶-4-基-1H-吲唑-3-胺被排除;或其盐。